What are the main active compounds in Buxus sempervirens?

The primary bioactive constituents are steroidal alkaloids concentrated at up to 3% in leaves and bark, including cyclovirobuxine D (antiproliferative, autophagy-inducing), cyclobuxine (antiretroviral, anti-inflammatory), buxine (anti-inflammatory, bitter principle), cyclomicrophyllidine-B (antiplasmodial, IC50 0.2 μM), parabuxine, and parabuxonidine. Minor constituents include tannins, volatile oil, and mineral salts, but these are not considered pharmacologically significant compared to the alkaloid fraction.

Has Buxus sempervirens been tested in clinical trials for HIV or cancer?

No randomized controlled trials have been completed for any indication. The only human-context data come from an uncontrolled observational report in which SPV-30 extract at 990 mg/day appeared to delay CD4 decline in HIV-positive individuals, while 1980 mg/day showed no benefit and possible harm from oxidative stress. Cancer research remains entirely in the in vitro stage, with no animal or human trials published.

What is the recommended dose of Buxus sempervirens extract?

There is no established or regulatory-approved supplemental dose for Buxus sempervirens in any jurisdiction. The only human dose with any reported association to a clinical endpoint is 990 mg/day of the SPV-30 commercial extract in an HIV observational context; the higher 1980 mg/day dose was associated with adverse oxidative effects. Due to the absence of safety and pharmacokinetic data, self-dosing is not recommended.

Is boxwood (Buxus sempervirens) safe to use as a herbal supplement?

The safety of Buxus sempervirens as a supplement is not established; all plant parts contain pharmacologically potent steroidal alkaloids with no defined safe dose in humans. Toxicity concerns are supported by the observed adverse oxidative stress at 1980 mg/day and by the inherent bioactivity of the alkaloid class. It is contraindicated in pregnancy and lactation and should only be used under medical supervision within a research framework.

What traditional diseases was boxwood used to treat historically?

European folk medicine used boxwood wood decoctions as an alterative and diaphoretic for rheumatism, arthritis, and syphilis—serving as a substitute for the tropical guaiacum resin. Leaf preparations were applied to skin ulcers and taken for malarial fever in North African and Near Eastern traditions, a use that has partial biochemical support from the discovery of antiplasmodial cyclomicrophyllidine-B. It was also used to induce sweating and lower fever, consistent with the alkaloids' known effects on autonomic and inflammatory pathways.

How does Buxus sempervirens trigger autophagy differently than standard cancer treatments?

Buxus sempervirens leaf extract activates autophagy—a cellular self-cleaning process—rather than apoptosis (programmed cell death), making it potentially effective against treatment-resistant cancers that have developed resistance to conventional therapies. Studies show the extract increases LC3II markers 2.2–3.3-fold and upregulates Beclin-1, indicating robust autophagy activation in melanoma, colorectal, and prostate cancer cell lines. This mechanism may offer an alternative approach for aggressive cancers that fail to respond to apoptosis-based drugs.

What forms of Buxus sempervirens extract show the strongest anticancer activity in research?

Hydroalcoholic leaf extracts (BSHE) have demonstrated the most compelling anticancer activity in laboratory studies, particularly against melanoma, HCT116 colorectal cancer, and PC3 prostate cancer cells. The hydroalcoholic preparation appears to efficiently extract and preserve the bioactive alkaloids responsible for autophagy induction. Other extraction methods and plant parts have not been similarly characterized for anticancer potency in published research.

Who should consider Buxus sempervirens supplementation based on current research evidence?

Current research is preliminary and limited to cell culture studies, so Buxus sempervirens cannot yet be recommended as a primary cancer treatment for any patient population. Individuals with treatment-resistant cancers or those interested in complementary approaches should discuss potential use with their oncologist, as the ingredient has not completed human clinical trials for efficacy or safety in cancer patients. The existing evidence is too early-stage to define appropriate candidate populations outside of controlled research settings.

Common Boxwood

Buxus sempervirens contains steroidal alkaloids—principally cyclovirobuxine D, cyclobuxine, buxine, and cyclomicrophyllidine-B—that induce cancer-cell autophagy, inhibit HIV reverse transcriptase, and suppress inflammatory mediators through modulation of apoptotic and immunological pathways. The most quantified preclinical signal is cyclovirobuxine D's induction of LC3II accumulation 2.2–3.3-fold in melanoma, colorectal, and prostate cell lines, alongside one observational report that 990 mg/day SPV-30 extract delayed HIV-related CD4 decline, though no randomized controlled trial has confirmed either finding.

Category: South American Evidence: 1/10 Tier: Preliminary

Origin & History

Buxus sempervirens is native to western and southern Europe, northwest Africa, and southwest Asia, thriving in calcareous, well-drained soils in woodland margins and rocky hillsides. It has been cultivated extensively as an ornamental shrub across temperate regions for millennia, with naturalized populations established in parts of North America. Although listed here under a South American folk medicine context, its bioactive alkaloid chemistry has been investigated primarily from European botanical specimens, with the variety suffruticosa studied for antiplasmodial alkaloids peaking in leaf concentration during May.

Historical & Cultural Context

Buxus sempervirens has been employed in European folk medicine for centuries, most prominently as a wood decoction used as a substitute for guaiacum resin in the treatment of syphilis and chronic rheumatic complaints, reflecting its historical association with alterative and 'blood-purifying' therapies. The bitter alkaloid buxine was recognized by herbalists as the active constituent responsible for its diaphoretic (sweat-inducing) and antipyretic properties, and leaf preparations were applied topically to indolent skin ulcers and fungal lesions. In North African and Near Eastern traditions, boxwood bark preparations were used to manage malarial fevers, a use that has since received partial biochemical validation through the discovery of antiplasmodial alkaloids including cyclomicrophyllidine-B. The tree's association with longevity and immortality in classical antiquity—it was sacred to Pluto and used to crown the dead—parallels modern interest in its antiproliferative alkaloid chemistry, though the historical medicinal corpus predates any understanding of its molecular pharmacology.

Health Benefits

- **Autophagy-Mediated Anticancer Activity**: Hydroalcoholic leaf extracts (BSHE) trigger autophagy in treatment-resistant melanoma (BMel), colorectal (HCT116), and prostate (PC3) cell lines by increasing LC3II 2.2–3.3-fold and transiently upregulating Beclin-1, suggesting utility against aggressive cancers unresponsive to apoptosis-based therapies.
- **Antiretroviral Potential**: Cyclobuxine inhibits HIV reverse transcriptase activity in vitro; an observational report of SPV-30 extract at 990 mg/day noted delayed CD4 cell decline in HIV-positive individuals, though the mechanism may involve direct enzyme inhibition rather than immune enhancement.
- **Anti-Inflammatory Action**: Buxine and related alkaloids suppress oxidative burst, inhibit neutrophil chemotaxis, reduce T-cell proliferation, and attenuate pro-inflammatory cytokine release, forming a multi-target anti-inflammatory profile relevant to rheumatic and autoimmune conditions.
- **Antiplasmodial Effects**: Cyclomicrophyllidine-B isolated from var. suffruticosa leaf extracts demonstrates potent in vitro antiplasmodial activity with an IC50 of 0.2 μM, a value competitive with reference antimalarials, providing a biochemical rationale for historical use against malarial fevers.
- **Anticholinesterase Activity**: Steroidal alkaloids from B. sempervirens inhibit acetylcholinesterase in biochemical assays, raising exploratory interest in neurodegenerative disease contexts, though no in vivo or clinical data currently support this application.
- **Immunomodulation**: The alkaloid fraction as a whole exerts immunosuppressive effects by blunting oxidative burst in phagocytes and curtailing T-cell cytokine output, which may underlie traditional applications for inflammatory joint disease and skin ulcers.
- **Antipyretic and Diaphoretic Uses**: Wood decoctions have been employed historically to induce diaphoresis and reduce fever, consistent with the alkaloids' ability to modulate autonomic and inflammatory signaling, though the precise molecular targets for these effects remain uncharacterized.

How It Works

Cyclovirobuxine D modulates apoptosis, cell proliferation, and migration signaling in cancer cells while also triggering autophagosome formation, evidenced by LC3-I to LC3-II conversion and punctate LC3 localization, suggesting activation of the PI3K/Beclin-1 autophagy axis and possible mTOR inhibition. Cyclobuxine interferes with HIV reverse transcriptase, an RNA-dependent DNA polymerase, thereby blocking early-stage viral replication and potentially slowing CD4 depletion at the 990 mg/day SPV-30 dose range. Cyclomicrophyllidine-B exerts antiplasmodial effects consistent with disruption of Plasmodium falciparum heme detoxification or membrane integrity at nanomolar concentrations (IC50 0.2 μM). Buxine and the broader alkaloid fraction suppress innate immune overactivation by inhibiting NADPH oxidase-dependent oxidative burst in neutrophils and downregulating pro-inflammatory cytokines, providing a mechanistic basis for the observed anti-inflammatory and immunosuppressive activity.

Scientific Research

The evidence base for Buxus sempervirens is confined almost entirely to in vitro cell-line studies and a single, unreplicated observational report, placing it firmly in the preclinical category with no completed randomized controlled trials. The strongest mechanistic data come from hydroalcoholic extract experiments on human cancer cell lines (BMel, HCT116, PC3) demonstrating autophagy induction, and from isolation studies of cyclomicrophyllidine-B showing IC50 0.2 μM against P. falciparum; neither dataset includes animal efficacy models sufficient to justify human dosing extrapolation. The sole human-relevant report involves the SPV-30 commercial extract tested at 990 and 1980 mg/day in HIV-positive individuals, where only the lower dose appeared to delay CD4 decline—an observation confounded by the absence of randomization, blinding, or a control arm. Systematic phytochemical profiling beyond cyclovirobuxine D and cyclomicrophyllidine-B is incomplete, and bioavailability data in any species are absent from the published literature.

Clinical Summary

No randomized controlled trials have evaluated Buxus sempervirens for any clinical indication, making formal evidence-based recommendations impossible. The only human-context data point is an uncontrolled observational report of SPV-30 extract (containing cyclobuxine) at 990 mg/day associated with delayed HIV disease progression and preserved CD4 counts, while the 1980 mg/day dose appeared to induce oxidative stress with no benefit—an inverted dose-response that has not been replicated or mechanistically resolved. Anticancer and antimalarial outcomes have been measured exclusively in cell culture and biochemical assays, without animal pharmacokinetic or efficacy models bridging to human dosing. Confidence in all reported clinical signals is very low, and the ingredient should not be used therapeutically outside controlled research settings.

Nutritional Profile

Buxus sempervirens is not consumed as a food and has no meaningful macronutrient or micronutrient contribution to human nutrition. The primary phytochemicals are steroidal alkaloids concentrated in leaves and bark at up to 3% dry weight, with cyclovirobuxine D, cyclobuxine, buxine, parabuxine, and parabuxonidine representing the main identified compounds; cyclomicrophyllidine-B peaks in May in var. suffruticosa leaf extracts with an IC50 of 0.2 μM antiplasmodial potency. Minor constituents include tannins, volatile oil (trace), chlorophyll, wax, resin, gum, and lignin in leaf tissue, plus bark mineral salts comprising sulphates of potassium and calcium, carbonates of calcium and magnesium, and phosphates of calcium, iron, and silica. Bioavailability of the alkaloids in humans is entirely uncharacterized; lipophilic steroidal alkaloids generally exhibit moderate intestinal absorption, but first-pass metabolism, plasma protein binding, and tissue distribution for these specific compounds have not been quantified.

Preparation & Dosage

- **Hydroalcoholic Extract (Research Standard)**: 100 g dried leaves macerated in 200 mL 50% ethanol, filtered to yield ~50 mg/mL; used as reference preparation in in vitro autophagy studies—no validated human dose derived from this preparation.
- **SPV-30 Commercial Extract**: Tested at 990 mg/day orally in an observational HIV context; associated with delayed CD4 decline. The 1980 mg/day dose produced apparent oxidative stress with no clinical benefit and is not recommended.
- **Traditional Wood Decoction**: Small quantities of heartwood simmered in water historically as a diaphoretic and alterative for rheumatism and syphilis; exact mass/volume ratios were never standardized in historical records.
- **Leaf Decoction (Folk Use)**: Fresh or dried leaves briefly boiled in water for topical application to skin ulcers or taken internally for fever; preparation method lacks standardization and carries alkaloid toxicity risk.
- **Standardization**: No commercial supplement is currently standardized to a specific alkaloid percentage; cyclovirobuxine D content serves as the most studied marker compound but no validated assay standard exists for consumer products.
- **Timing**: No pharmacokinetic data exist to inform dosing frequency or optimal timing relative to meals.

Synergy & Pairings

No controlled synergy studies have been conducted for Buxus sempervirens with any other ingredient, and formal stack data are absent from the literature. Theoretically, combining boxwood alkaloids with established autophagy modulators such as hydroxychloroquine or rapamycin analogues could produce additive or antagonistic effects on the LC3II/Beclin-1 pathway, but this requires experimental validation. The observational concern that flavonoid co-administration at 1980 mg/day may have induced oxidative stress suggests that concurrent high-dose polyphenol stacks could paradoxically impair, rather than enhance, the intended antioxidant or antiviral effects of boxwood alkaloids.

Safety & Interactions

The safety profile of Buxus sempervirens in humans is poorly characterized; the alkaloids are pharmacologically active and inherently bitter, consistent with significant biological potency and potential toxicity at elevated doses. The only documented human dose-response signal is that 1980 mg/day SPV-30 extract appeared to induce oxidative stress in HIV-positive individuals, suggesting a narrow or inverted therapeutic window even for the commercial extract form. No formal drug interaction studies exist, but the anticholinesterase activity of boxwood alkaloids creates a theoretical risk of potentiated toxicity with cholinergic medications (e.g., acetylcholinesterase inhibitors such as donepezil) and a possible interaction with antiretroviral drug metabolism via cytochrome P450 pathways. Boxwood is contraindicated in pregnancy and lactation due to complete absence of safety data and known alkaloid bioactivity; it should not be used as a self-administered supplement by any population given the absence of established safe doses, clinical oversight requirements, and its non-food historical classification.